{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:55:17Z","timestamp":1792803317321,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02966-7","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:22:37Z","timestamp":1777278157000},"page":"1343-1351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Chronic myelomonocytic leukemia beyond the marrow: biology, patterns, and management of extramedullary disease"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0428-1105","authenticated-orcid":false,"given":"Manal","family":"Ahmidouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Salib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Abdel Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2966_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2966_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2966_CR3","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428\u201336.","journal-title":"J Clin Oncol"},{"key":"2966_CR4","first-page":"1610","volume":"106","author":"MM Patnaik","year":"2021","unstructured":"Patnaik MM, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Hanson CA. Extramedullary disease in chronic myelomonocytic leukemia is associated with adverse outcomes: Mayo Clinic experience. Haematologica. 2021;106:1610\u201320.","journal-title":"Haematologica"},{"key":"2966_CR5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"2966_CR6","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1080\/10428194.2018.1452212","volume":"59","author":"K Hoversten","year":"2018","unstructured":"Hoversten K, Vallapureddy R, Lasho T, Finke C, Ketterling R, Hanson C, et al. Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates. Leuk lymphoma. 2018;59:2998\u20133001.","journal-title":"Leuk lymphoma"},{"key":"2966_CR7","first-page":"1157","volume":"8","author":"B Gipe","year":"2023","unstructured":"Gipe B, Arvanitis M, Patel V, Lamba R, Zhao S, Wang JC. Renal involvement in chronic myelomonocytic leukemia: a clinicopathologic study of 20 patients. Kidney Int Rep. 2023;8:1157\u201365.","journal-title":"Kidney Int Rep"},{"key":"2966_CR8","doi-asserted-by":"crossref","unstructured":"Loghavi S, Zang C, Li Z, Hammond D, Chien K, Bataller A Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition. Blood. 2025;146:3838.","DOI":"10.1182\/blood-2025-3848"},{"key":"2966_CR9","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1182\/bloodadvances.2025016529","volume":"9","author":"G Montalban-Bravo","year":"2025","unstructured":"Montalban-Bravo G, Loghavi S, Li Z, Chien K, Kanagal-Shamanna R, Bataller A, et al. Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia. Blood Adv. 2025;9:5105\u201317.","journal-title":"Blood Adv"},{"key":"2966_CR10","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.21037\/tcr-19-2882","volume":"9","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Jian J, Deng L, Tian H, Liu B. Leukaemia cutis as a specific skin involvement in chronic myelomonocytic leukaemia and review of the literature: Acknowledgments. Transl Cancer Res. 2020;9:4988\u201398.","journal-title":"Transl Cancer Res"},{"key":"2966_CR11","doi-asserted-by":"publisher","first-page":"e37159","DOI":"10.1097\/MD.0000000000037159","volume":"103","author":"F Li","year":"2024","unstructured":"Li F, Zhao J, Duan H, Zhang H, Zhang L, Zhao L, et al. Pyoderma gangrenosum complicated with hematological malignancies: Two case reports. Med (Balt). 2024;103:e37159.","journal-title":"Med (Balt)"},{"key":"2966_CR12","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1600-0609.2009.01226.x","volume":"82","author":"CC Sung","year":"2009","unstructured":"Sung CC, Chang PY, Wu YY, Hsu YC, Chiang CP, Chen YC. Pyoderma gangrenosum as initial presentation of chronic myelomonocytic leukemia. Eur J Haematol. 2009;82:410.","journal-title":"Eur J Haematol"},{"key":"2966_CR13","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1378\/chest.128.3.1406","volume":"128","author":"HFMJ Nadrous","year":"2005","unstructured":"Nadrous HFMJ, Decker PA, Ryu JH. Pulmonary manifestations of chronic myelomonocytic leukemia: a retrospective study of 55 patients. Chest. 2005;128:1406\u201314.","journal-title":"Chest"},{"key":"2966_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100769","volume":"6","author":"RM Attieh","year":"2024","unstructured":"Attieh RM, Begum F, Chitty D, Izzedine H, Jhaveri KD. Kidney and urinary tract involvement in chronic myelomonocytic leukemia. Kidney Med. 2024;6:100769.","journal-title":"Kidney Med"},{"key":"2966_CR15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5414\/CNP63229","volume":"63","author":"Y Terada","year":"2005","unstructured":"Terada Y, Nakayama T, Fukaya M. Membranous nephropathy associated with chronic myelomonocytic leukemia. Clin Nephrol. 2005;63:229\u201333.","journal-title":"Clin Nephrol"},{"key":"2966_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1084\/jem.124.5.921","volume":"124","author":"EF Osserman","year":"1966","unstructured":"Osserman EF, Lawlor DP. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med. 1966;124:921\u201352.","journal-title":"J Exp Med"},{"key":"2966_CR17","first-page":"911","volume":"77","author":"KD Nolph","year":"1972","unstructured":"Nolph KD, Schrier RW, Alfrey AC, Kleeman CR. Renal complications of myelomonocytic leukemia: the role of lysozyme. Ann Intern Med. 1972;77:911\u20138.","journal-title":"Ann Intern Med"},{"key":"2966_CR18","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1016\/j.ekir.2023.09.005","volume":"8","author":"MC Lafargue","year":"2023","unstructured":"Lafargue MC, Bobot M, Rennke HG, Essig M, Carre M, Mercadal L, et al. Chronic myelomonocytic leukemia patients with lysozyme nephropathy and renal infiltration display markers of severe disease. Kidney Int Rep. 2023;8:2733\u201341.","journal-title":"Kidney Int Rep"},{"key":"2966_CR19","first-page":"1035","volume":"50","author":"T Sugimoto","year":"2011","unstructured":"Sugimoto T, Kume H, Ishida M. Ureteral obstruction caused by extramedullary involvement of chronic myelomonocytic leukemia. Intern Med. 2011;50:1035\u20139.","journal-title":"Intern Med"},{"key":"2966_CR20","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1182\/blood-2015-01-620781","volume":"125","author":"D Selimoglu-Buet","year":"2015","unstructured":"Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125:3618\u201326.","journal-title":"Blood"},{"key":"2966_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96:375\u201383.","journal-title":"Haematologica"},{"key":"2966_CR22","unstructured":"Savona MR G-MG, Mason CC. An international cohort study of azacitidine and decitabine outcomes in CMML. Blood. 2013;121:828\u201335."},{"key":"2966_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10522-020-09858-y","volume":"21","author":"DV Gospodaryov","year":"2020","unstructured":"Gospodaryov DV, Strilbytska OM, Semaniuk UV, Perkhulyn NV, Rovenko BM, Yurkevych IS, et al. Correction to: Alternative NADH dehydrogenase extends lifespan and increases resistance to xenobiotics in Drosophila. Biogerontology. 2020;21:173\u20134.","journal-title":"Biogerontology"},{"key":"2966_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41375-024-02466-6","volume":"39","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, et al. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025;39:257\u201360.","journal-title":"Leukemia"},{"key":"2966_CR25","first-page":"2224","volume":"127","author":"EPJ Padron","year":"2016","unstructured":"Padron EPJ, Kunigal S, Mailloux AW, McGraw KL, McDaniel JM, Kim E, Kumar S, List AF, Komrokji R. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Blood. 2016;127:2224\u201331.","journal-title":"Blood"},{"key":"2966_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"A Symeonidis","year":"2015","unstructured":"Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171:239\u201346.","journal-title":"Br J Haematol"},{"key":"2966_CR27","first-page":"308","volume":"41","author":"C Zhao","year":"2020","unstructured":"Zhao C, Huang XJ, Zhao XS, Wang Y, Yan CH, Xu LP, et al. [Impact of splenomegaly on outcomes of allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020;41:308\u201312.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2966_CR28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ajh.25246","volume":"93","author":"P Pophali","year":"2018","unstructured":"Pophali P, Horna P, Lasho TL, Finke CM, Ketterling RP, Gangat N, et al. Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients. Am J Hematol. 2018;93:1347\u201357.","journal-title":"Am J Hematol"},{"key":"2966_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1182\/blood-2017-04-736421","volume":"130","author":"E Solary","year":"2017","unstructured":"Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130:126\u201336.","journal-title":"Blood"},{"key":"2966_CR30","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142\u201365.","journal-title":"Am J Hematol"},{"key":"2966_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01245-5","volume":"15","author":"A Bataller","year":"2025","unstructured":"Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study. Blood Cancer J. 2025;15:50.","journal-title":"Blood Cancer J"},{"key":"2966_CR32","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","volume":"22","author":"E Padron","year":"2016","unstructured":"Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, et al. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016;22:3746\u201354.","journal-title":"Clin Cancer Res"},{"key":"2966_CR33","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1182\/blood-2024-202867","volume":"144","author":"D Hiwase","year":"2024","unstructured":"Hiwase D, Ross DM, Yeung DT, Yong AS, Lane SW, Brown A, et al. Durable responses observed in chronic myelomonocytic leukemia treated with lenzilumab and azacitidine. Blood. 2024;144:1006.","journal-title":"Blood"},{"key":"2966_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100126","volume":"2","author":"A Aribi","year":"2025","unstructured":"Aribi A, Mannis GN, Madanat YF, Jonas BA, Dunavin N, Roboz GJ, et al. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood Neoplasia. 2025;2:100126.","journal-title":"Blood Neoplasia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02966-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02966-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:55:55Z","timestamp":1782917755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02966-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2966"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02966-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DT receives contracted research funding paid to his institution from Sobi, Sumitomo, Geron, and Cogent Biosciences and consulting fees from Sobi, Refined Oncology, AbbVie, Pharmaessentia, Geron, GSK and Cogent Biosciences. Somedeb Ball received contracted research funding paid to his institution from Crossbow Therapeutics. Patrick Brunner receives personal fees from Almirall, Sanofi, Janssen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Novartis, UCB, Merck, RAPT Therapeutics, Galderma, Immunocore, TD Securities, Apogee and Bristol Myers Squibb. PMB receives research support from Pfizer (grant paid to his institution) and is an investigator for Pfizer and Abbvie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}